JP7671305B2 - ２型アンギオテンシンｉｉ受容体アゴニストの新規使用 - Google Patents

２型アンギオテンシンｉｉ受容体アゴニストの新規使用 Download PDF

Info

Publication number
JP7671305B2
JP7671305B2 JP2022557150A JP2022557150A JP7671305B2 JP 7671305 B2 JP7671305 B2 JP 7671305B2 JP 2022557150 A JP2022557150 A JP 2022557150A JP 2022557150 A JP2022557150 A JP 2022557150A JP 7671305 B2 JP7671305 B2 JP 7671305B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
respiratory
treatment
virus
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520323A (ja
JP2023520323A5 (https=
Inventor
ダルスガード，カール－ヨハン
ラウド，ヨハン
バッタ，ロヒト
Original Assignee
ヴィコール ファルマ アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004209.9A external-priority patent/GB202004209D0/en
Priority claimed from GBGB2009574.1A external-priority patent/GB202009574D0/en
Application filed by ヴィコール ファルマ アーベー filed Critical ヴィコール ファルマ アーベー
Publication of JP2023520323A publication Critical patent/JP2023520323A/ja
Publication of JP2023520323A5 publication Critical patent/JP2023520323A5/ja
Application granted granted Critical
Publication of JP7671305B2 publication Critical patent/JP7671305B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022557150A 2020-03-23 2021-03-22 ２型アンギオテンシンｉｉ受容体アゴニストの新規使用 Active JP7671305B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB2004209.9A GB202004209D0 (en) 2020-03-23 2020-03-23 New use
GB2004209.9 2020-03-23
GB2009574.1 2020-06-23
GBGB2009574.1A GB202009574D0 (en) 2020-06-23 2020-06-23 New use
US17/113,416 US11123329B1 (en) 2020-03-23 2020-12-07 Use of angiotensin II type 2 receptor agonist
US17/113,416 2020-12-07
PCT/GB2021/050699 WO2021191592A1 (en) 2020-03-23 2021-03-22 New use of angiotensin ii type 2 receptor agonist

Publications (3)

Publication Number Publication Date
JP2023520323A JP2023520323A (ja) 2023-05-17
JP2023520323A5 JP2023520323A5 (https=) 2024-04-03
JP7671305B2 true JP7671305B2 (ja) 2025-05-01

Family

ID=77747178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557150A Active JP7671305B2 (ja) 2020-03-23 2021-03-22 ２型アンギオテンシンｉｉ受容体アゴニストの新規使用

Country Status (12)

Country Link
US (2) US11123329B1 (https=)
EP (1) EP4125881B1 (https=)
JP (1) JP7671305B2 (https=)
CN (1) CN115605201A (https=)
CA (1) CA3176108A1 (https=)
ES (1) ES2992423T3 (https=)
HR (1) HRP20241435T1 (https=)
HU (1) HUE068662T2 (https=)
PL (1) PL4125881T3 (https=)
RS (1) RS66072B1 (https=)
SM (1) SMT202400427T1 (https=)
WO (1) WO2021191592A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202004094D0 (en) * 2020-03-20 2020-05-06 Vicore Pharma Ab New compounds and uses
US20220233480A1 (en) * 2020-03-23 2022-07-28 Vicore Pharma Ab Use of angiotensin ii type 2 receptor agonist
AU2021258178A1 (en) * 2020-04-22 2022-11-17 Airway Therapeutics, Inc. Use of surfactant protein D to treat viral infections
US20240408065A1 (en) * 2021-09-30 2024-12-12 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Cyano compound, and preparation method therefor and use thereof
CN115583984A (zh) * 2022-01-11 2023-01-10 嘉兴安谛康生物科技有限公司 氮杂螺类化合物及其制备方法、药物组合物和用途
CN114948950A (zh) * 2022-01-19 2022-08-30 广州谷森制药有限公司 一种药物组合物及其抗病毒用途
WO2024153020A1 (zh) * 2023-01-16 2024-07-25 海南先声药业有限公司 抗病毒药物组合物及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507244A (ja) 2015-03-02 2018-03-15 ビーコレ ファルマ アクティエボラーグ 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1529697B (zh) 2001-05-31 2010-09-22 维科尔药物公司 用作血管紧张素ⅱ激动剂的三环化合物
EP1723962A1 (en) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507244A (ja) 2015-03-02 2018-03-15 ビーコレ ファルマ アクティエボラーグ 肺線維症の治療のためのアンギオテンシンｉｉ受容体作動薬

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU, Cynthia et al.，Reasearch and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases，ACS Central Science，2020年03月12日，vol.6, no.3，pp.315-331
WANG, Di et al.，Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanisical ventilation，Pulmonary Pharmacology & Therapeutics，2019年，vo.58, 101833，pp.1-6

Also Published As

Publication number Publication date
ES2992423T3 (es) 2024-12-12
US11123329B1 (en) 2021-09-21
CN115605201A (zh) 2023-01-13
EP4125881A1 (en) 2023-02-08
JP2023520323A (ja) 2023-05-17
US20210386712A1 (en) 2021-12-16
EP4125881C0 (en) 2024-07-24
RS66072B1 (sr) 2024-11-29
CA3176108A1 (en) 2021-09-30
SMT202400427T1 (it) 2024-11-15
HUE068662T2 (hu) 2025-01-28
PL4125881T3 (pl) 2024-12-02
US20210290596A1 (en) 2021-09-23
HRP20241435T1 (hr) 2024-12-20
WO2021191592A1 (en) 2021-09-30
EP4125881B1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
JP7671305B2 (ja) ２型アンギオテンシンｉｉ受容体アゴニストの新規使用
RU2766577C2 (ru) Способы лечения эозинофильного эзофагита
CN114929209A (zh) 肌萎缩侧索硬化的治疗
US12551469B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
Riha et al. Novel therapies for angiotensin-converting enzyme inhibitor–induced angioedema: a systematic review of current evidence
JP2013529627A (ja) ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
US20230129866A1 (en) Methods of treating respiratory disease with deupirfenidone
US20250268876A1 (en) Treatment of hidradenitis suppurativa with orismilast
JP2023517194A (ja) コロナウイルス感染の処置における組合せに使用するためのｐｌｄ
JP2026505367A (ja) 高タンパク尿慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの合剤
US20220233480A1 (en) Use of angiotensin ii type 2 receptor agonist
US20200352974A1 (en) Response-guided hcv therapy
TW201204360A (en) Treatment of multiple sclerosis with MASITINIB
US11160814B1 (en) Methods of treatment for disease from coronavirus exposure
HK40081689A (en) New use of angiotensin ii type 2 receptor agonist
HK40081689B (en) New use of angiotensin ii type 2 receptor agonist
TW202144380A (zh) 用於治療冠狀病毒感染之化合物
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
WO2023192779A2 (en) Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
EA052469B1 (ru) Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250325

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250418

R150 Certificate of patent or registration of utility model

Ref document number: 7671305

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150